We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A health advocacy group is demanding that the FDA remove three members of its Psychopharmacologic Advisory Committee who had done research, consulting and other work for manufacturers of antidepressant drugs, even though the committee recently urged the agency to issue stronger warnings about increased suicide risk among children taking those drugs.